DE19802708A1 - Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren - Google Patents
Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und DruckgeschwürenInfo
- Publication number
- DE19802708A1 DE19802708A1 DE19802708A DE19802708A DE19802708A1 DE 19802708 A1 DE19802708 A1 DE 19802708A1 DE 19802708 A DE19802708 A DE 19802708A DE 19802708 A DE19802708 A DE 19802708A DE 19802708 A1 DE19802708 A1 DE 19802708A1
- Authority
- DE
- Germany
- Prior art keywords
- atoms
- hydroxy
- pyridone
- formula
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 208000005230 Leg Ulcer Diseases 0.000 title claims abstract description 14
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 title claims abstract description 12
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical class ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 title claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- -1 1-hydroxy-2-pyridone compound Chemical class 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 3
- 150000003254 radicals Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 claims description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical group [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000416 hydrocolloid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QUAMONVCYKMUNY-UHFFFAOYSA-N 1-hydroxy-4-methyl-6-[[4-(3-phenylprop-2-enoxy)phenoxy]methyl]pyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OCC=CC1=CC=CC=C1 QUAMONVCYKMUNY-UHFFFAOYSA-N 0.000 description 1
- CMJRXUFGEJJSCZ-UHFFFAOYSA-N 1-hydroxy-4-methyl-6-[[4-[4-(trifluoromethyl)phenoxy]phenoxy]methyl]pyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(C(F)(F)F)C=C1 CMJRXUFGEJJSCZ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- AGIAYOIJHFTOSV-UHFFFAOYSA-N 3-(2-phenylethyl)-1h-pyridin-2-one Chemical compound O=C1NC=CC=C1CCC1=CC=CC=C1 AGIAYOIJHFTOSV-UHFFFAOYSA-N 0.000 description 1
- WBXDEEFCGDIKFC-UHFFFAOYSA-N 6-(3-bicyclo[2.2.1]heptanyl)-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1C1C(C2)CCC2C1 WBXDEEFCGDIKFC-UHFFFAOYSA-N 0.000 description 1
- BRAAURUJHFSPTE-UHFFFAOYSA-N 6-[(4-benzylphenoxy)methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1CC1=CC=CC=C1 BRAAURUJHFSPTE-UHFFFAOYSA-N 0.000 description 1
- FICIDNLKUZDFQS-UHFFFAOYSA-N 6-[[4-(2,4-dichlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1Cl FICIDNLKUZDFQS-UHFFFAOYSA-N 0.000 description 1
- NOMIBIVUURZCPM-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-3,4-dimethylpyridin-2-one Chemical compound ON1C(=O)C(C)=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 NOMIBIVUURZCPM-UHFFFAOYSA-N 0.000 description 1
- WQRDQQATCFVLNN-UHFFFAOYSA-N 6-[[4-[(2,4-dichlorophenyl)methoxy]phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OCC1=CC=C(Cl)C=C1Cl WQRDQQATCFVLNN-UHFFFAOYSA-N 0.000 description 1
- MJQVWFQOPJBTIP-UHFFFAOYSA-N 6-[[4-[(2,4-dichlorophenyl)methyl]phenoxy]methyl]-1-hydroxy-3,4-dimethylpyridin-2-one Chemical compound ON1C(=O)C(C)=C(C)C=C1COC(C=C1)=CC=C1CC1=CC=C(Cl)C=C1Cl MJQVWFQOPJBTIP-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000012943 effectiveness check Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical compound [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19802708A DE19802708A1 (de) | 1998-01-24 | 1998-01-24 | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
| CZ20002664A CZ295316B6 (cs) | 1998-01-24 | 1999-01-11 | Léčivo k léčbě bércových vředů a proleženin |
| AT99902528T ATE360418T1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
| IL13745399A IL137453A (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for the production of a medicament for the treatment of leg ulcers and decubitus ulcers |
| ES99902528T ES2285829T3 (es) | 1998-01-24 | 1999-01-11 | Uso de preparados en polvo que contienen hidroxipiridona para el tratamiento de ulceras de los miembros inferiores y ulceras por presion. |
| DE59914312T DE59914312D1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
| TR2000/02118T TR200002118T2 (tr) | 1998-01-24 | 1999-01-11 | Baldırdaki ülserlerin ve dekubitik ülserlerin tedavisinde pudra müstahzarlarının kullanılması. |
| EP99902528A EP1049468B1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
| AU22787/99A AU752406B2 (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| PCT/EP1999/000105 WO1999037300A1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
| CN99802327A CN1128619C (zh) | 1998-01-24 | 1999-01-11 | 含有羟基吡啶酮的粉末制剂用于治疗腿部溃疡和压迫溃疡的用途 |
| HK01104925.1A HK1034447B (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| MEP-2008-559A ME00390B (me) | 1998-01-24 | 1999-01-11 | Primjena prepaparata u obliku praha koji sadrži hidroksipiridon za tretman ulkusa na potkoljenici ili dekubitusnog ulcera |
| JP2000528282A JP5127091B2 (ja) | 1998-01-24 | 1999-01-11 | 下腿潰瘍および圧迫性潰瘍の治療のためのヒドロキシピリドン含有粉末製剤の使用 |
| PT99902528T PT1049468E (pt) | 1998-01-24 | 1999-01-11 | Utilização de preparações em pó contendo hidroxipiridona para o tratamento de úlceras da perna e úlceras de pressão |
| US09/600,903 US6534528B1 (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| CA002319359A CA2319359C (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| KR1020007008050A KR100597332B1 (ko) | 1998-01-24 | 1999-01-11 | 하이드록시피리돈을 함유하는 하지 괴저 및 욕창 궤양 치료용 약제학적 분말 조성물 |
| RU2000122313/14A RU2212239C2 (ru) | 1998-01-24 | 1999-01-11 | Применение гидроксипиридонсодержащей препаративной формы в виде присыпки для лечения варикозной язвы и пролежней |
| YUP-437/00A RS50903B (sr) | 1998-01-24 | 1999-01-11 | Primena preparata u obliku pudera koji sadrži hidroksipiridon za tretman ulkusa na potkolenici ili dekubitusnog ulcera |
| PL342055A PL192550B1 (pl) | 1998-01-24 | 1999-01-11 | Zastosowanie zasypki i związku hydroksypirydonowego |
| SI9930962T SI1049468T1 (sl) | 1998-01-24 | 1999-01-11 | Uporaba praškastih pripravkov, ki vsebujejo hidroksipiridon, za zdravljenje golenskih razjed in preležanin |
| SK1089-2000A SK285350B6 (sk) | 1998-01-24 | 1999-01-11 | Použitie prášku a najmenej jedného 1-hydroxy-2-pyridónu |
| NZ505898A NZ505898A (en) | 1998-01-24 | 1999-01-11 | Powder preparations containing hydroxypyridones; useful for treating leg ulcers and/or decubitus ulcers |
| HU0200851A HU228824B1 (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| HR20000496A HRP20000496A2 (en) | 1998-01-24 | 1999-01-11 | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| BR9907734-5A BR9907734A (pt) | 1998-01-24 | 1999-01-11 | Emprego de preparados em pó contendo hidroxipiridona para o tratamento de tumores da perna e de pressão |
| DK99902528T DK1049468T3 (da) | 1998-01-24 | 1999-01-11 | Anvendelse af hydroxypyridonholdige pudderpræparater til behandling af skinnebens- og tryksår |
| ARP990100243A AR016445A1 (es) | 1998-01-24 | 1999-01-21 | Procedimiento de utilizacion de preparaciones en polvo que contienen 1-hidroxi-2-piridona para la preparacion de un medicamento para el tratamiento de ulceras en la pierna y ulceras de presion |
| CY20071100855T CY1106684T1 (el) | 1998-01-24 | 2007-06-28 | Χρησιμοποιηση σκευασματων πουδρας που περιεχουν υδροξυπυριδονη για την αγωγη εξελκωσεων κνημης και εξελκωσεων λογω κατακλισης |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19802708A DE19802708A1 (de) | 1998-01-24 | 1998-01-24 | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19802708A1 true DE19802708A1 (de) | 1999-07-29 |
Family
ID=7855595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19802708A Withdrawn DE19802708A1 (de) | 1998-01-24 | 1998-01-24 | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
| DE59914312T Expired - Lifetime DE59914312D1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59914312T Expired - Lifetime DE59914312D1 (de) | 1998-01-24 | 1999-01-11 | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6534528B1 (https=) |
| EP (1) | EP1049468B1 (https=) |
| JP (1) | JP5127091B2 (https=) |
| KR (1) | KR100597332B1 (https=) |
| CN (1) | CN1128619C (https=) |
| AR (1) | AR016445A1 (https=) |
| AT (1) | ATE360418T1 (https=) |
| AU (1) | AU752406B2 (https=) |
| BR (1) | BR9907734A (https=) |
| CA (1) | CA2319359C (https=) |
| CY (1) | CY1106684T1 (https=) |
| DE (2) | DE19802708A1 (https=) |
| DK (1) | DK1049468T3 (https=) |
| ES (1) | ES2285829T3 (https=) |
| HR (1) | HRP20000496A2 (https=) |
| HU (1) | HU228824B1 (https=) |
| IL (1) | IL137453A (https=) |
| ME (1) | ME00390B (https=) |
| NZ (1) | NZ505898A (https=) |
| PL (1) | PL192550B1 (https=) |
| PT (1) | PT1049468E (https=) |
| RS (1) | RS50903B (https=) |
| RU (1) | RU2212239C2 (https=) |
| SI (1) | SI1049468T1 (https=) |
| SK (1) | SK285350B6 (https=) |
| TR (1) | TR200002118T2 (https=) |
| WO (1) | WO1999037300A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001122804A (ja) * | 1999-10-28 | 2001-05-08 | Sato Pharmaceutical Co Ltd | リン酸コーンスターチ配合外用医薬組成物 |
| EP1354586A1 (en) * | 2002-04-20 | 2003-10-22 | Aventis Pharma Deutschland GmbH | The use of hydroxpyridone-derivatives in wound healing |
| US20060257439A1 (en) * | 2005-03-29 | 2006-11-16 | Sabnis Ram W | Cleansing compositions with color changing indicator |
| RU2326665C1 (ru) * | 2007-04-03 | 2008-06-20 | Марвел ЛайфСайнсез Лимитед, Великобритания | Средство, обладающее противогипоксическим, противоинсультным, улучшающим память действием |
| MX2013001095A (es) * | 2010-07-27 | 2013-03-12 | Clariant Finance Bvi Ltd | Composiciones que comprenden peroxido de hidrogeno o sustancias donadoras de peroxido de hidrogeno. |
| ES2525388T3 (es) * | 2010-07-27 | 2014-12-23 | Clariant Finance (Bvi) Limited | Utilización de hidroxipiridonas o de sus sales para la estabilización del peróxido de hidrógeno o de unas sustancias que ponen en libertad peróxido de hidrógeno |
| RS61907B1 (sr) | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2540218A (en) | 1947-08-25 | 1951-02-06 | Squibb & Sons Inc | 2-hydroxy-pyridine-n-oxide and process for preparing same |
| EP0241918B1 (de) * | 1986-04-18 | 1992-05-27 | Hoechst Aktiengesellschaft | 1-Hydroxy-2-pyridone, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten, sowie bei der Herstellung der 1-Hydroxy-2-pyridone gebildete Zwischenprodukte |
| JPS63264504A (ja) * | 1987-04-17 | 1988-11-01 | Shinto Paint Co Ltd | 工業用防カビ組成物 |
| US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
| CA2046801C (en) * | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| DE4333893A1 (de) * | 1993-10-05 | 1995-04-06 | Hoechst Ag | Kosmetische Zubereitungen |
| DE59609219D1 (de) * | 1995-12-04 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen |
-
1998
- 1998-01-24 DE DE19802708A patent/DE19802708A1/de not_active Withdrawn
-
1999
- 1999-01-11 ME MEP-2008-559A patent/ME00390B/me unknown
- 1999-01-11 WO PCT/EP1999/000105 patent/WO1999037300A1/de not_active Ceased
- 1999-01-11 HR HR20000496A patent/HRP20000496A2/hr not_active Application Discontinuation
- 1999-01-11 TR TR2000/02118T patent/TR200002118T2/xx unknown
- 1999-01-11 AT AT99902528T patent/ATE360418T1/de active
- 1999-01-11 EP EP99902528A patent/EP1049468B1/de not_active Expired - Lifetime
- 1999-01-11 DE DE59914312T patent/DE59914312D1/de not_active Expired - Lifetime
- 1999-01-11 NZ NZ505898A patent/NZ505898A/en not_active IP Right Cessation
- 1999-01-11 RU RU2000122313/14A patent/RU2212239C2/ru active
- 1999-01-11 RS YUP-437/00A patent/RS50903B/sr unknown
- 1999-01-11 DK DK99902528T patent/DK1049468T3/da active
- 1999-01-11 SK SK1089-2000A patent/SK285350B6/sk not_active IP Right Cessation
- 1999-01-11 IL IL13745399A patent/IL137453A/xx not_active IP Right Cessation
- 1999-01-11 PL PL342055A patent/PL192550B1/pl unknown
- 1999-01-11 AU AU22787/99A patent/AU752406B2/en not_active Expired
- 1999-01-11 PT PT99902528T patent/PT1049468E/pt unknown
- 1999-01-11 ES ES99902528T patent/ES2285829T3/es not_active Expired - Lifetime
- 1999-01-11 CA CA002319359A patent/CA2319359C/en not_active Expired - Lifetime
- 1999-01-11 JP JP2000528282A patent/JP5127091B2/ja not_active Expired - Lifetime
- 1999-01-11 BR BR9907734-5A patent/BR9907734A/pt not_active Application Discontinuation
- 1999-01-11 HU HU0200851A patent/HU228824B1/hu unknown
- 1999-01-11 SI SI9930962T patent/SI1049468T1/sl unknown
- 1999-01-11 US US09/600,903 patent/US6534528B1/en not_active Expired - Lifetime
- 1999-01-11 KR KR1020007008050A patent/KR100597332B1/ko not_active Expired - Lifetime
- 1999-01-11 CN CN99802327A patent/CN1128619C/zh not_active Expired - Lifetime
- 1999-01-21 AR ARP990100243A patent/AR016445A1/es unknown
-
2007
- 2007-06-28 CY CY20071100855T patent/CY1106684T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68910138T2 (de) | Fumagillin als angiostatisches Mittel. | |
| DE69434490T2 (de) | Zusammenstellungen zur Krebsbehandlung | |
| KR890001881B1 (ko) | 크림기제 조성물 | |
| DE60037816T2 (de) | Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka | |
| DE3205504A1 (de) | Aeusserlich anwendbares, ibuprofen enthaltendes arzneimittel | |
| DE60029340T2 (de) | Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran | |
| EP0130550A2 (de) | Auf Schleimhäute des Mundes, der Nase und/oder des Rachens wirkende Arzneimittel auf der Basis von Heparin und Tensiden | |
| EP1049468B1 (de) | Verwendung von hydroxypyridon-haltigen puderzubereitungen zur behandlung von unterschenkel- und druckgeschwüren | |
| EP0285856B1 (de) | Verwendung von Dihydroergotamin und seinen Salzen zur lokalen Behandlung trophischer Störungen | |
| DE69220050T2 (de) | Verfahren zur inhibierung der fibrose | |
| WO2001051525A1 (de) | Heparin mit mittlerer molmasse | |
| DE2746761C2 (de) | Verwendung von 2-Pyrrolidonderivaten zur Behandlung von Gefäßerkrankungen beim Menschen | |
| DE102004034913A1 (de) | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren | |
| EP2570124A1 (en) | Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics | |
| EP0865278B1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen | |
| EP4618950B1 (de) | Stoffgemisch zur anwendung bei der topischen behandlung eines onkologischen hand-fuss-syndroms, und verfahren zur herstellung des stoffgemischs | |
| EP0442063B1 (de) | Verwendung von 2',4',6'-Trimethoxy-4-(1-pyrrolidinyl)butyrophenon zur lokalen Behandlung von trophischen Erkrankungen | |
| DE69806248T2 (de) | Pharmazeutische zubereitung zur behandlung sogenannter rastloser beine | |
| WO2025232973A1 (de) | Klinoptilolith oder klinoptilolith enthaltendes mineralstoffgemisch zur verwendung als mineralische wundabdeckung | |
| CZ20002664A3 (cs) | Léčivo k léčbě bércových vředů a proleženin | |
| DE2231989A1 (de) | Pharmazeutisches praeparat | |
| Scherf et al. | Akuter fieberhafter Rheumatismus | |
| HU208251B (en) | Process for producing pharmaceutical compositions for reducing vasodilatation of veins | |
| MXPA00007000A (en) | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers | |
| DE2119096A1 (en) | Topical compsns contg 3-oxo-17-beta-acetoxy-oestra- - 4,9,11-triene - for treatment of pressure sores and varicose ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, 65929 FRANKFURT, |
|
| 8141 | Disposal/no request for examination |